drugset / Trial / NCT00447915
Phase II/III Clinical Study of R484iv (Ibandronic Acid) for Primary Osteoporosis
RandomizedParallel-groupQuadruple-blindTreatment
Summary
To evaluate the efficacy and safety of R484iv by intravenous intermittent administration to patients with primary osteoporosis in comparison with sodium risedronate hydrate (RIS) by oral administration every day. To evaluate also the dose response of R484iv.
Timeline
- Start
- 2007-03
- Primary completion
- 2011-08
- Completion
- 2011-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ibandronic acid | Unknown | 0.5 mg | Intravenous |
| Subject | Ibandronic acid | Unknown | 1 mg | Intravenous |
| Comparator | Sodium Risedronate Hydrate | Unknown | 2.5 mg | Oral |